In a recently published narrative review article authored by Gomez-Huelgas and colleagues, authors propose an interesting treatment algorithm, based on the cardiovascular and renal protection offered by newer antidiabetic drug classes [1]. According to the consensus report published by the American Diabetes Association and the European Association for the Study of Diabetes in 2020, glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors are prioritized for the treatment of patients with type 2 diabetes mellitus (T2DM) to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (HF), cardiovascular death, or chronic kidney disease (CKD) development and progression, regardless of glycemic control [2].
